Emergent BioSolutions, Aptevo deal

Biodefense company Emergent completed its spin out of newco Aptevo, which will house Emergent’s oncology and hematology assets. Aptevo’s marketed products include hemophilia drug Ixinity trenonacog alfa. Its pipeline includes Emergent’s ADAPTIR platform, including bispecific therapeutics based on redirected T cell cytotoxicity; and MOR209/ES414, a bispecific ADAPTIR molecule targeting prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) and CD3, which is in Phase I testing to treat metastatic castration-resistant prostate cancer. Aptevo product sales for 1Q16 were $7.9 million. In 2014, Emergent and MorphoSys AG (Xetra:MOR, Martinsried, Germany) partnered to develop ES414. Ixinity is a Factor IX replacement. ...